

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



吉林省輝南長龍生化藥業股份有限公司

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8049)

**(1) DELAY IN PUBLICATION OF ANNUAL RESULTS AND
POSSIBLE DELAY IN DESPATCH OF ANNUAL REPORT;
(2) PUBLICATION OF UNAUDITED ANNUAL RESULTS
ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021;
AND
(3) NOTICE OF BOARD MEETING**

This announcement is made by Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities (the “**GEM Listing Rules**”) on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

DELAY IN PUBLICATION OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021 AND POSSIBLE DELAY IN DESPATCH OF ANNUAL REPORT

Under Rules 18.49 and 18.48A of the GEM Listing Rules, the Company was required to publish the announcement in relation to the preliminary audited annual results of the Group for the year ended 31 December 2021 (the “**2021 Annual Results**”) on a date no later than three months after the end of the financial year of the Company, i.e. on or before 31 March 2022 and despatch its annual report (the “**2021 Annual Report**”) to the shareholders of the Company (the “**Shareholders**”) on or before 31 March 2022. As travel and other restrictions were put in place due to the recent outbreak of coronavirus disease 2019 (COVID-19), the reporting and audit processes of the Group were adversely affected and the Company is unable to publish an annual results announcement for FY2021.

The board of directors (the “**Board**”) of the Company (the “**Directors**”) wishes to inform the Shareholders and potential investors of the Company that it is unlikely that the Company will be able to publish the 2021 Annual Results and despatch 2021 Annual Report by 31 March 2022 in accordance with Rules 18.49 and 18.48A of the GEM Listing Rules.

Notwithstanding this, the Board wishes to emphasize that the operation of the Group remains normal and that it will continue to work with the Auditor closely to publish the 2021 Annual Results and despatch of 2021 Annual Report to the Shareholders. The 2021 Annual Results and 2021 Annual Report are expected to be published by the end of April 2022.

PUBLICATION OF UNAUDITED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021

In order to keep the Shareholders and potential investors of the Company informed of the Group’s business operation and financial position, the Board has decided to publish the unaudited annual results of the Group for the year ended 31 December 2021 (the “**2021 Unaudited Annual Results**”) on 31 March 2022.

The Board will review and approve, among other things, the publication of the 2021 Unaudited Annual Results based on the management accounts of the Group for the year ended 31 December 2021.

NOTICE OF BOARD MEETING

The board hereby announces that a meeting of the Board will be held at Economic Development Zone, Chaoyang Town, Huinan County, Tonghua, Jilin Province (吉林省通化市輝南縣朝陽鎮經濟開發區), the PRC on Thursday, 31 March 2022 at 10:00 a.m. for the following purposes:

1. To consider and approve the unaudited consolidated financial statements for the year ended 31 December 2021 of the Company and its subsidiaries, and to approve the associated draft announcement and a summary of the unaudited final results thereof to be published on the GEM website;
2. To consider the payment of final dividend, if any;
3. To consider the closure of the Register of Members, if necessary; and
4. To transact any other business.

The Company will keep the Shareholders and the public informed of the development of the matter by making further announcement(s) as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
Zhang Hong
Chairman

Jilin Province, the PRC
21 March 2022

As at the date of this announcement, the Board comprises six executive directors, being Zhang Hong, Zhang Xiao Guang, Zhao Bao Gang, Wu Guo Wen, Zhang Yi and Xu Xiang Fu; and three independent non-executive directors, being Gao Qi Pin, Ban Jun Gui and Tian Jie.

This announcement, for which the directors of Jilin Province Huinan Changlong Bio-pharmacy Company Limited collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to Jilin Province Huinan Changlong Bio-pharmacy Company Limited. The directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the “Latest Company Announcements” page on the GEM Website at www.hkgem.com for at least 7 days from the date of its posting.